Cwm LLC Boosts Illumina, Inc. Stake by 22.8%

The institutional investor now owns over 135,000 shares of the life sciences company.

Apr. 18, 2026 at 8:13am

Got story updates? Submit your updates here. ›

An extreme close-up of the inner workings of a DNA sequencing machine, with a focus on the precision engineering and industrial design that powers Illumina's advanced genomics technology.Cwm LLC's increased investment in Illumina highlights the institutional investor's confidence in the life sciences company's cutting-edge genomics technology.San Diego Today

Cwm LLC, an institutional investor, increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 22.8% during the fourth quarter, according to a recent 13F filing. The firm now owns 135,535 shares of the life sciences company's stock, worth approximately $17.8 million.

Why it matters

Illumina is a leading global provider of DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The company's products are used by academic institutions, pharmaceutical and biotechnology companies, and government laboratories around the world. Cwm LLC's increased stake in Illumina reflects the firm's confidence in the company's long-term growth prospects.

The details

According to the 13F filing, Cwm LLC acquired an additional 25,160 shares of Illumina during the fourth quarter, bringing its total position to 135,535 shares. This represents approximately 0.09% of Illumina's outstanding shares. The institutional investor's increased stake in Illumina comes as the company continues to expand its product portfolio and market reach in the rapidly growing genomics industry.

  • Cwm LLC filed the 13F report disclosing its Illumina holdings in the fourth quarter of 2026.
  • The firm increased its Illumina stake by 22.8% compared to the previous quarter.

The players

Cwm LLC

An institutional investor that manages assets for clients, including pension funds, endowments, and high-net-worth individuals.

Illumina, Inc.

A global life sciences company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and function.

Got photos? Submit your photos here. ›

The takeaway

Cwm LLC's increased stake in Illumina reflects the institutional investor's confidence in the life sciences company's long-term growth potential. As a leading provider of DNA sequencing and array-based technologies, Illumina is well-positioned to benefit from the ongoing expansion of the genomics industry.